We want your opinions about HIV and health care. Your opinions will be used to develop a campaign to help others with HIV get into and stay in care. Eligible persons will take part in a one-on-one interview lasting up to one hour and receive $75 for their time and travel.
This research is being done by RTI International with funding from the Centers for Disease Control and Prevention (CDC).
If you are interested, please go to: http://thehennegroup.com/prescreener/
The interviews are taking place in Washington D.C. and Los Angeles, CA.
THG contracted with the American College of Cardiology to conduct 55 one-hour interviews with cardiologists, primary care physicians, nurse practitioners, and cardiac patients with cardiovascular disease in Chicago, Baltimore, Fort Lauderdale, San Francisco and Jackson, MS. The research was conducted in support of Take Action, a 2008 initiative whose goal was to decrease the chances of a secondary coronary event for those who have just recently been discharged from a hospital after being hospitalized with acute coronary syndrome (ACS).
For this study, THG recruited 39 healthcare professionals, 14 of whom had a patient population that was at least 50 percent African-American. We also recruited 16 cardiac patients, 11 of whom were African-American.
THG was engaged by the Research Triangle Institute (RTI) in support of a communications project for the CDC to evaluate HIV messages for advertisements aimed at increasing HIV testing among young African-American MSM. THG successfully recruited this target audience to participate in individual interviews and focus groups. This research began in 2009 and is ongoing through 2011, as the CDC refines and evaluates the effectiveness of the campaign.
The goal of this research is to pretest HIV testing messages and ascertain comprehension, personal relevance, efficacy, persuasiveness, acceptability of content, and to obtain feedback and opinions on channels for message placement.
Since the start of this project, THG has recruited over 300 respondents in Atlanta, Oakland, Newark, Detroit, Charlotte, Raleigh, Miami, and Washington DC. We have interviewed MSM who have been tested for HIV in the past 12 months and MSM who have not been tested for HIV in the past 12 months. All participants have been between the ages of 18-44. We are currently recruiting for an additional 81 interviews in Atlanta, Los Angeles, and New York.
The data obtained from these interviews will be used to revise existing and create new campaign messages for HIV testing social marketing campaigns targeting African American MSM.
Since 2008, THG has conducted over a dozen qualitative and quantitative projects for Gilead Sciences – all of which involve the recruiting of hard-to-reach populations. In a 2008 study, THG recruited 80 participants across eight cities to conduct a total of 65 one-hour interviews. This was an extremely difficult recruit – participants had to meet a patient profile, and were estimated to be approximately 5% of the total patient population. Even with the difficult recruiting specifications, the entire timeline of this project was only 10 weeks.
In 2010, THG was contracted to provide qualitative research which involved recruiting 540 HIV-diagnosed patients who had not yet taken medication for their HIV for participation in a 40-minute survey in English or Spanish. Outreach was conducted via health clinics and non-profit organizations supplemented by internet and telephone outreach data gathering.
In late 2010, THG conducted two studies for Gilead involving the recruitment of focus groups and one-on-one interviews in the Phoenix area. For one study, nine HIV-positive females between the ages of 32 and 64 were screened using very specific eligibility criteria regarding their date of HIV diagnosis and their medication regimen. For the other, 13 men and women of varying ethnicity and sexual orientation between the ages of 23 and 64 were screened using similarly specific criteria.
In 2010, THG collaborated with Lilly to develop an instrument to measure treatment satisfaction and the effect of treatment on psychosocial concerns for men with ED. The research involved a series of focus groups and in-depth interviews conducted across the nation with men with ED. Respondents were required to fit a very specific patient profile, satisfying eligibility criteria regarding their age, sexual activity, sexual dysfunction and use of medication to treat their sexual dysfunction.
A total of 227 men were recruited for participation in this study. For the second phase of the project, THG recruited 24 participants for in-depth interviews and 29 participants for focus groups. 13 of the participants were Phoenix residents between the ages of 27 and 67.
THG is currently working on the second phase of a project intended to establish a patient-reported outcome measure of testosterone deficiency in men for clinical trials and labeling purposes. This study requires a similar outreach effort, recruiting respondents fitting a very specific patient profile. For the first phase, 72 men between the ages of 30 and 81 were recruited for focus groups and in-depth interviews. Part of the second phase’s participant population will be comprised of 12 patients and six doctors treating testosterone deficiency in the Phoenix area.
For both of these studies, THG used and is using a variety of outreach methods, including internet outreach through Craigslist and Facebook, print advertising, and outreach through medical offices, libraries and retirement homes
THG conducted three studies for the BPRI Group, a research-led consultancy based in London focusing on business-to-business research. THG sourced sample, recruited and conducted 47 one-hour in-person interviews, 34 half-hour telephone interviews and two focus groups with state senators, representatives, assembly members and district supervisors, as well as global opinion leaders from non-governmental organizations, including senior representatives from national energy companies, government officials, academics and informed public.